The new company combines Coster’s products and complementary offerings from Lindal Group to create a distinctive portfolio of spray packaging solutions for pharmaceutical applications. It is thus ideally positioned from the start to seize the growth opportunities in this sector. RxPack will be located in Oggiono, north of Milan in Italy, and is expected to start operations at the end of this year.
With RxPack (pronounced R-x-Pack), there will be a new provider of pharmaceutical packaging solutions with a distinctive and highly competitive product portfolio. RxPack will be one of the three leading players in the sector, thus having the opportunity to stimulate momentum and drive innovation among all sector participants. This will greatly benefit pharmaceutical companies and their customers alike.
“Our goal is to create a new strong player in the field of packaging solutions for pharmaceutical applications. RxPack has the expertise, the products and the financial strength to provide our pharmaceutical customers with innovative solutions that significantly improve the health and lives of sick people”, explains Martina Segatta, Chair of the Board and majority shareholder of Coster. “With RxPack, we create a powerful setup dedicated to the pharmaceutical sector that will enable us to serve this mission excellently and make the most of the opportunities in this sector.”
RxPack combines pharmaceutical businesses
RxPack will combine the highly complementary product lines of Lindal and Coster with spray packaging solutions for pharmaceutical applications: pulmonary inhalation devices such as MDIs, nasal devices such as nasal pumps and other aerosol and dispensing solutions for the regulated and non-regulated pharmaceutical sectors. Additionally, RxPack will be the exclusive distribution channel for Coster’s aerosol filling machines for pharmaceutical applications, excluding BOVs.
RxPack will start its business with about 60 employees of Coster and Lindal who bring special expertise for the pharmaceutical business. Furthermore, the company will hire additional specialized employees that are critical to the company’s success. The staff will be located at the production facility of Lindal in Oggiono which offers excellent working and production conditions including cleanrooms and laboratories.
Owner families are the driving forces behind the new company
Coster and Lindal will initially invest four million EUR in upgrading and extending clean room manufacturing capabilities. Further investments and R&D plans will target entering the highly attractive regulated sector and extending the product portfolio with innovative alternative pharmaceutical packaging solutions.
RxPack’s investments and R&D plans also reflect the motivation of the owner families behind Coster and Lindal. Martina Segatta, just like Katharina Lilienthal, Chairwoman of the Board of Lindal, has been a strong supporter of the establishment of RxPack from the beginning and firmly endorses the substantial investments to expand the range of high-quality and innovative solutions for customers. Their companies, Coster and Lindal, will each have an equal share in RxPack.
RxPack will be a stand-alone company
Coster and Lindal will continue to be competitors outside of RxPack. The new company will therefore operate completely independent from both groups and with a stand-alone organization and separate facilities, as the Oggiono site will be exclusively dedicated to RxPack. RxPack will solely focus on the pharmaceutical sector, a segment requiring special expertise and manufacturing technology, and thus on the production and distribution of products used exclusively targeting this sector.
Coster and Lindal will focus on their core business, serving customers in the personal care, home care, technical and industrial sectors. The manufacturing of the BOV products, however, will remain at Coster and Lindal. Since they are based on a different technology and address different segments in addition to the pharmaceutical sector, Lindal and Coster will both continue to offer BOV products, also for pharmaceutical applications, and remain strong competitors in this area.
